Max Robotics — Global Service Robot Directory + US Certification

About

Tuomas Mirtti is a leading translational researcher in prostate cancer, whose work bridges surgical pathology, molecular biology, and artificial intelligence. His key research areas include prostate cancer diagnostics, biomarker discovery, and the integration of novel tissue fixation methods with clinical outcomes. Mirtti’s major contributions span from validating PAXgene fixation for high-fidelity molecular and histomorphologic analysis—enabling robust translational studies—to developing an AI model for prostate biopsies that predicts cancer survival, a breakthrough with 19 citations that promises to refine clinical decision-making. He has also demonstrated that adding prostate MRI to established nomograms (CAPRA, MSKCC, Partin) significantly enhances prediction of adverse findings and biochemical recurrence after radical prostatectomy (17 citations). His work on transrectal biopsy performance has informed focal therapy strategies, while his 11-year prospective analysis of health-related quality of life in the PRIAS active surveillance cohort (5 citations) provides critical long-term patient-reported outcomes. With over 20 citations for his foundational PAXgene study and a growing portfolio of impactful, clinically relevant research, Mirtti is a key figure advancing precision diagnostics and personalized treatment in prostate cancer.